GE HealthCare Gets Market Perform Rating, Faces Fraud Probe, Cuts EPS to $4.80–$5.00
GEHC•GE HealthCare received a Market Perform rating from BMO Capital as it faces a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP and has cut full-year adjusted EPS guidance to $4.80–$5.00. The company also launched a theranostics research collaboration with Mayo Clinic after a supplier-related recall.
1. Market Perform Rating and Outlook
On July 8, BMO Capital initiated coverage of GE HealthCare with a Market Perform rating, implying the stock should track the broader market. The company, with a market capitalization near $29.4 billion, is set to report second-quarter 2026 results on July 29 followed by a management conference call.
2. Securities Fraud Investigation
GE HealthCare is under a securities fraud investigation led by the law firm Glancy Prongay Wolke & Rotter LLP, focusing on potential federal securities law violations and investor losses. The probe adds legal uncertainty as the company navigates its revised financial targets.
3. EPS Guidance Cut and Recall Impact
Following first-quarter results, GE HealthCare lowered its full-year adjusted EPS guidance to a range of $4.80–$5.00, citing weaker profitability. Management attributed the downgrade in part to a supplier-related product recall that weighed on margins.
4. Mayo Clinic Theranostics Collaboration
Despite these challenges, GE HealthCare announced a new research collaboration with Mayo Clinic to advance personalized cancer theranostics, aiming to develop targeted diagnostic and treatment approaches. This partnership underscores the company’s commitment to innovation in oncology solutions.
